CN1714823A - Use of dripping pill in preparing medicine for treating anti-aspirin - Google Patents
Use of dripping pill in preparing medicine for treating anti-aspirin Download PDFInfo
- Publication number
- CN1714823A CN1714823A CN 200410019838 CN200410019838A CN1714823A CN 1714823 A CN1714823 A CN 1714823A CN 200410019838 CN200410019838 CN 200410019838 CN 200410019838 A CN200410019838 A CN 200410019838A CN 1714823 A CN1714823 A CN 1714823A
- Authority
- CN
- China
- Prior art keywords
- aspirin
- borneolum syntheticum
- parts
- application
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims description 68
- 239000006187 pill Substances 0.000 title claims description 40
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 49
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 49
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 69
- 238000011282 treatment Methods 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 18
- -1 sublimed preparation Substances 0.000 claims description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 11
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 9
- 206010002383 Angina Pectoris Diseases 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 208000029078 coronary artery disease Diseases 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims 1
- 208000025870 aspirin resistance Diseases 0.000 abstract description 37
- 238000012360 testing method Methods 0.000 abstract description 7
- 240000007164 Salvia officinalis Species 0.000 abstract description 5
- 230000000747 cardiac effect Effects 0.000 abstract description 3
- 208000019553 vascular disease Diseases 0.000 abstract description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract description 2
- 229940116229 borneol Drugs 0.000 abstract description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract description 2
- 235000005412 red sage Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 105
- 239000000706 filtrate Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000003756 stirring Methods 0.000 description 23
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 20
- 239000000811 xylitol Substances 0.000 description 20
- 235000010447 xylitol Nutrition 0.000 description 20
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 20
- 229960002675 xylitol Drugs 0.000 description 20
- 239000007788 liquid Substances 0.000 description 18
- 235000010489 acacia gum Nutrition 0.000 description 16
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 16
- 239000008899 fufang danshen Substances 0.000 description 16
- 238000009413 insulation Methods 0.000 description 16
- 229940057995 liquid paraffin Drugs 0.000 description 16
- 239000012141 concentrate Substances 0.000 description 15
- 238000002156 mixing Methods 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 14
- 238000002844 melting Methods 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- 238000011084 recovery Methods 0.000 description 14
- 229920002472 Starch Polymers 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000008107 starch Substances 0.000 description 13
- 235000019698 starch Nutrition 0.000 description 13
- 238000007493 shaping process Methods 0.000 description 12
- 230000002745 absorbent Effects 0.000 description 11
- 239000002250 absorbent Substances 0.000 description 11
- 238000012856 packing Methods 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 229920002545 silicone oil Polymers 0.000 description 9
- 230000004520 agglutination Effects 0.000 description 8
- 239000002826 coolant Substances 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000010257 thawing Methods 0.000 description 7
- 235000017276 Salvia Nutrition 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000000391 smoking effect Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000010118 platelet activation Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 206010002388 Angina unstable Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229930004069 diterpene Natural products 0.000 description 3
- 125000000567 diterpene group Chemical group 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 2
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- XYKZSUXWBGUGQV-UHFFFAOYSA-N 4,8-dimethylnaphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound CC1=CC=CC2=C(C(C=3OC=C(C=3C3=O)C)=O)C3=CC=C21 XYKZSUXWBGUGQV-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 2
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 2
- 101150062589 PTGS1 gene Proteins 0.000 description 2
- 101150000187 PTGS2 gene Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- 241001072909 Salvia Species 0.000 description 2
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000013172 carotid endarterectomy Methods 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical group OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 1
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 241001252601 Blumea Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 1
- 241000123611 Dipterocarpaceae Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229940067131 aspirin 100 mg Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- YTJJRAWFHJBAMT-UHFFFAOYSA-N depside Natural products OC(=O)CC1=C(O)C=C(O)C=C1OC(=O)C1=CC=C(O)C(O)=C1 YTJJRAWFHJBAMT-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- XHALVRQBZGZHFE-UHFFFAOYSA-N rosmarinic acid methyl ester Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(=O)OC)CC1=CC=C(O)C(O)=C1 XHALVRQBZGZHFE-UHFFFAOYSA-N 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides the new use of a kind of medicine composition. The medicine composition consists of red sage, notoginseng, borneol, etc. Clinical test shows that the medicine composition has the property of improving aspirin resistance and may be used in treating aspirin resistance cardiac vascular diseases to raise the life quality of the aspirin resistance cardiac vascular disease patient.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to the application of a kind of drop pill in preparation treatment resistant medication of aspirin.
Background technology
Aspirin (Aspirin) claim aspirin or aspirin again, is applied to clinical existing more than 80 year history, is a kind of ancient analgesic, analgesic.Along with the going deep into of prostaglandin research, aspirin there has been new understanding again in recent years: analgesic except being used for traditionally clinically, analgesia, the antiinflammatory, also be used for antiplatelet aggregation etc.Clinical trial shows that aspirin is the effective antiplatelet drug of cardiovascular and cerebrovascular disease high-risk patient primary prevention, and is also effective to the secondary prevention of myocardial infarction and ischemic vascular events.
But use the aspirin of therapeutic dose at present clinically, still there is part cardiovascular and cerebrovascular disease patient that coronary artery thrombus and apoplexy have taken place, strengthen therapeutic dose, not only fail to reach treatment and prevention purpose, and untoward reaction increases, this phenomenon be called " aspirin resistance " (Aspirin Resistance, AR).
Through long term follow-up, reason is as follows: first platelet is by other pathway activation, can not be blocked [Valles J by aspirin, Santos MT, Aznar J, et al.Erythrocyte Promotion of platelet reactivity decreases the effectivenessof aspirin as an antithrombotic therapeutic modality:the effect of low-dose aspirin is less thanoptimal in patients with vascular disease due to prothrombotic effects of erythrocytes on plateletreactivity.Circulation, 1998; 97:350-355]; The dosage that second some needs of patients is bigger than routine dose just can obtain best thromboembolism preventing effect, there is not evidence to show relevant [the Patrono C.Prevention ofmyocardial infarction and stroke by aspirin:different mechanisms of aspirin thromboembolism preventing effect with dosage? Different dosage? Thromb.Res., 1998; 92:S7-S12]; Although using the routine dose aspirin, the 3rd some patient also can generate TXA
2[Tayllor DW, Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy:arandomized controlled trail; ASA and Carotid Endarterectomy (ACE) Trial Collaborators.Lancet, 1999; 353:2179-2184].
Studies show that the generation of AR is relevant with following mechanism.
Erythrocyte improves platelet response
Platelet-erythrocyte interacts influence platelet response, synthesizes and platelet is raised and caused aspirin resistance by platelet release reaction, eicosanoids.Erythrocyte causes TXA
2Synthetic increasing, 5-HT, β-TG and ADP discharge, generation [the Valles J that shows erythrocyte adjusting platelet eicosanoids, et al.Erythrocyte metabolically enhancescollagen-induced platelet responsiveness via increased thromboxane production, adenosinediphosphate release, and recruitment.Blood, 1991; 78:154-162].
Arachidonic acid (PGF
2
) metabolism
Arachidonic acid produces a series of bioactive PGF that have through lipid peroxidation
2See complex.F
2-isoprostanes is the important new predictor of angiopathy.Unstable angina, stable angina pectoris, ariant angina patient and healthy people take aspirin 100mg/d and measure 8-iso-PGF
2(mark of matter fat peroxidation) and 11 dehydrogenations-TXA
2(TXA
2Studies show that biosynthetic mark), unstable angina patient 8-iso-PGF
2Urinary excretion is apparently higher than stablizing patient with angina pectoris and matched group; TXA
2Excretion apparently higher than stable patient with angina pectoris.Unstable angina patient's oxidant stress increases, 8-iso-PGF
2Increase, platelet is to the increased response of other agonist.
Smoking stimulates
Smoking is the cardiovascular disease principal risk factor.Data shows that aspirin can the anticoagulant rate reduce platelet aggregation [the Davis JW that causes, et al.Cigarette smoking-induced enhancement of platelet function:lack ifprevention by aspirin in men with coronary artery disease.J Lab Clin Med, 1982; 126:637-639].Platelet aggregation rate reduces after the smoking.Take aspirin before non-smoker and the smoking addiction person smoking and can prevent that platelet aggregation rate from descending.
The catecholamine levels platelet increasing is assembled to be increased
External platelet shows adrenergic sensitivity and has contact [Larsson PT et al between platelet activation that catecholamine causes and the acute coronary syndrome, Norepinephrine-induced human platelet activation in vivo is only partlycounteracted bv aspirin.Circulation, 1994; 89:1951-1957].40 patients of acute myocardial infarction are divided into warfarin group and aspirin group at random.Get blood before and after the bicycle ergometor exercise, relatively two groups baseline characteristic, movement time and maximum heart rate.The warfarin group obviously reduces than aspirin group platelet aggregation rate when baseline, illustrates that aspirin has the effect of antiplatelet aggregation.Two groups platelet aggregation rate all reduces during motion, shows that the platelet aggregation ability increases.Its reason may be that the increase of noradrenaline rope level causes platelet activation.
Platelet increases the sensitivity of collagen
Collagen is the agonist of physiological important platelet aggregation.Two experimental study aspirin reply and collagen between relation.Before aspirin 324mg/kg is taken in a test (n=8 healthy male), measure the bleeding time after taking medicine 2 hours, distinguish aspirin respondent and nonresponder.87 of philtrums have participated in second test, give collagen 0.15-4 μ g/ml and determine aspirin respondent and the nonresponder's platelet sensitivity to collagen.Among 8 patients of first test, 5 aspirin respondents, 3 nonresponders.Aspirin respondent and the nonresponder preceding bleeding time indifference [(408 ± 121) and (330 ± 30) second, P＞0.05] of taking medicine has significant difference [(720 ± 225) and (330 ± 52) second] after taking medicine.Among 7 patients of second test, 4 aspirin respondents, 3 nonresponders.Aspirin respondent and the nonresponder preceding bleeding time indifference [(405 ± 52) and (357 ± 31) second of taking medicine, P＞0.05], significant difference [(623 ± 189) and (345 ± 54) second] [Kawasaki T is arranged after taking medicine, el at.Incresed platelet sensitivity to cllagen in individuals resistant to low aspirin.Stroke, 2000; 31:591-595].
Cycloxygenase-2 (COX-2) (p900)
Cox is the synthetic rate-limiting enzyme of prostaglandin.Cox-1 expresses in most cells and tissue.In the great majority tissue, can not detect under the mRNA of Cox-2 and the protein normal condition.[Weber AA, et al.Cyclooxygenase-2 in human platelet as a possible factor in aspirin resistance.Lancet, 1993 such as nearest Webr; 353:900] report that protein and the mRNA of Cox-2 express in healthy people's circulation platelet, this may be a reason of aspirin resistance.
Drug interaction
The interaction of aspirin and other nonsteroidal anti inflammatory medicines (NSAIDS) can weaken aspirin to hematoblastic effect.Aspirin needs at first to combine lysine-the 120th, the coefficient site of all NSAIDS with lysine-120 to the acetylation of serine residue.NSAIDS is stronger to the affinity of lysine-120, thereby has stoped the inhibitory action of aspirin to platelet Cox-1.
More than set forth possible mechanisms of aspirin resistance.Clear and definite platelet activation mechanism and reversible risk factor help to reduce the generation of aspirin resistance, improve patient's prognosis.
Aspirin resistance can not effectively stop thromboxane A after being meant and taking aspirin
2Synthetic, promptly aspirin has lost the protective effect to cardio-cerebrovascular, this phenomenon is referred to as aspirin resistance.Concerning Most patients, aspirin can make cardiovascular danger reduce by 25%, but the patient of aspirin resistance uses the aspirin for treatment cardiovascular disease, can not prevent the generation of cardiovascular event, can increase the incidence rate of heart infarction and apoplexy on the contrary, these find the use of restriction aspirin.Therefore, these cardiovascular disease are referred to as aspirin repellency cardiovascular disease in the middle of the present invention, particularly refer to coronary heart disease, the angina pectoris of using aspirin for treatment invalid.The present invention will be referred to as the medicine of anti-aspirin resistance to the medicine that aspirin repellency cardiovascular disease has a therapeutical effect, and this therapeutical effect is referred to as anti-aspirin resistance effect.
At present, the report for the treatment aspirin resistance also is not a lot.[Effects of pretreatment withclopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneouscoronary intervention:the PCI-CURE study.Lancet, 2001] such as Yusuf S have been reported to add on the basis of aspirin for treatment and have been adjoined Gray with chlorine and can reduce the incidence rate that Acute Coronary Syndrome Patients comprises the early stage and secular serious cardiovascular incident of patient of percutaneous coronary intervention (pci).
The Chinese medicine blood-regulating drug, particularly the blood-activating stasis-removing kind medicine is the medicine that ancient Chinese medicine doctor is used always, this class medicine has the disappear effect of addiction, blood-activating analgetic, detumescence and promoting granulation of promoting blood flow to regulate menstruation, removing blood stasis, modern pharmacology confirms, blood-regulating drug has the expansion coronary artery, increases coronary flow, reduce myocardial oxygen consumption, reduce peripheral vascular resistance, anticoagulant, microcirculation improvement, suppress thrombosis, fortifying fibre protein dissolution activity, anticoagulation system, microcirculation improvement, effects such as smooth muscle spasm are alleviated in blood pressure lowering.The clinical effect of Rhizoma Chuanxiong in the blood-regulating drug, Radix Salviae Miltiorrhizae, Herba Leonuri, Semen Persicae, Flos Carthami, Hirudo etc. is constantly expanded, and particularly the research of Radix Salviae Miltiorrhizae is particularly outstanding.
The Radix Salviae Miltiorrhizae bitter in the mouth, cold nature has blood circulation promoting and blood stasis dispelling, nourishing blood to tranquillize the mind, the effect of removing heat from blood row's carbuncle and toxin expelling granulation promoting is the common drug of Chinese medicine blood circulation promoting and blood stasis dispelling.The red rooted salvia master contains fat-soluble Diterpenes composition and water miscible liposoluble ingredient, still contains other compositions such as flavonoid, triterpenes, sterol.What belong to quinone, ketone type structure in the Diterpenes composition has Tanshinone I, IIA, an II
R, V, VI, cryptotanshinone, iso tanshinone I, II, II
B, dihydrotanshinone I etc.Water miscible liposoluble ingredient has depside that danshensu, protocatechualdehyde, protocatechuic acid, caffeic acid and danshensu and caffeinic derivant or dimer esterification form such as salvianolic acid A, B, C, D, E, G, alkannic acid B, rosmarinic acid, rosmarinic acid methyl ester etc.Tanshinone is one of representative composition of Radix Salviae Miltiorrhizae Diterpenes blood circulation promoting and blood stasis dispelling.Modern pharmacological research proof Radix Salviae Miltiorrhizae has coronary artery dilator, resists myocardial ischemia, anticoagulant, antithrombotic formation, sedation-analgesia and effects such as blood fat reducing and atherosclerosis.
Radix Notoginseng belongs to hemostasis class Chinese medicine.Chinese medicine thinks that it has the hemostasis of becoming silted up of loosing, and the function of subduing swelling and relieving pain is not only stopped blooding but also invigorate blood circulation.The existing anastalsis of modern pharmacological research proof Radix Notoginseng has blood coagulation resisting function again.Anastalsis comprises and shortens clotting time, platelet increasing quantity and make it occur stretch pseudopodium, assemble, take off phenomenon such as granule, can also reduce capillary permeability.What show blood coagulation resisting function is part composition in the Radix Notoginseng: the total soap formula of Radix Notoginseng, Radix Notoginseng panoxadiol type soap summation triol type soap formula, they all can suppress the gathering of people and rabbit platelet.The total soap formula of Radix Notoginseng can promote vascular endothelial cell secretory tissue type plasminogen (t-N), stops the formation of thrombosis.
Borneolum Syntheticum is the processing crystallization product of the outstanding brain balsam of Dipterocarpaceae plant.The crystallization that the leaf of Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb gets through water vapour distillation processing is called Blumeae preparatum Tabellae.Be called BORNEOLUM SYNTHETICUM by Camphora, Lignum Pini Nodi wet goods with the synthetic product of being processed into of chemical method.The hot hardship of loosing of Borneolum Syntheticum is let out, and fragrance is walked string, can lead to all keys, and the stagnated fire of loosing has similar merit of shielding the fragrant refreshment of having one's ideas straightened out.Borneol mainly closes right family Borneolum Syntheticum; Blumeae preparatum Tabellae mainly closes left-handed Borneolum Syntheticum.Modern pharmacological research proof Borneolum Syntheticum has the effect that resists myocardial ischemia, and coronary flow is obviously increased; In addition, Borneolum Syntheticum can also increase the permeability of blood brain barrier, strengthens medicine and strides the barrier ability.
Find that through secular clinical research the traditional Chinese medical science thinks that the etiology and pathology of coronary heart disease is many because " imbalance of YIN and YANG, mechanism of qi be contrary to cause disorderly that the painstaking effort stasis of blood stagnates, blockage of the cardiac vessels, stagnation of QI and blood may bring about pain ".According to mentioned above principle, the someone has chosen Radix Salviae Miltiorrhizae, Radix Notoginseng, Borneolum Syntheticum and suitable adjuvant and has made preparation, and said preparation has the effect of blood circulation promoting and blood stasis dispelling, is used for the angina pectoris that the coronary disease disease causes.Because its determined curative effect, untoward reaction is few, is clinical treatment coronary heart disease, uncomfortable in chest, anginal Chinese patent medicine commonly used.At present the research of said preparation is mainly concentrated in the research of the angina pectoris that the coronary disease disease causes, the effect of relevant said preparation treatment aspirin resistance does not appear in the newspapers as yet.
Summary of the invention
The object of the present invention is to provide the application of a kind of dropping pill formulation in the medicine of the anti-aspirin resistance of preparation.
Following drug component of the present invention is formed, consumption all has the low anti-curative effect of anti-preferably aspirin: 30～180 parts of Radix Salviae Miltiorrhizaes, 5～40 parts of Radix Notoginseng, 0.3～2.5 part of Borneolum Syntheticum, 10～40 parts of adjuvants; Preferred each component, consumption are 75～115 parts of Radix Salviae Miltiorrhizaes, 14～20 parts of Radix Notoginseng, 0.8～1.2 part of Borneolum Syntheticum, 15～30 parts of adjuvants; Best each component, consumption are 90 parts of Radix Salviae Miltiorrhizaes, 17.6 parts of Radix Notoginseng, 1 part of Borneolum Syntheticum, 20 parts of adjuvants.
Used adjuvant can be a present pharmaceutical industry adjuvant commonly used among the present invention, preferred Polyethylene Glycol; The best is a polyethylene glycol 6000.
Medicine of the present invention can be made any medicament on the pharmaceutics, and preferred medicine type is drop pill, spray, sublimed preparation, pill, granule, capsule, tablet, electuary, powder, oral liquid.
The preparation of effective ingredient of the present invention can be adopted following method: water extraction, decoction and alcohol sedimentation technique, extraction, infusion process, percolation, reflux extraction, continuous backflow extraction method, macroreticular resin absorbing method preparation.For example, these crude drug pulverize mix homogeneously can be made powder takes after mixing it with water; Also can be with these medicines decocting together, the condensed water decocting liquid is made oral liquid then; But, preferably adopt following technology to extract, but this can not limit protection scope of the present invention to raw material in order to make each crude drug of this medicine bring into play drug effect better.
Get Radix Salviae Miltiorrhizae 90g, Radix Notoginseng 17.6g, Borneolum Syntheticum 1g, polyethylene glycol 6000 20g are standby;
Get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water three times, collecting decoction filters, filtrate concentrates, and adds 2 times of amount 95% ethanol, leaves standstill 24 hours, filters, recovery ethanol is concentrated into relative density 1.33～1.35 (55～60 ℃); Getting Borneolum Syntheticum is dissolved in the adequate amount of ethanol, (1) (2) are added in the Polyethylene Glycol of water-bath thawing, stir evenly, be incubated 70 ± 2 ℃, select the dropper of suitable bore for use, speed with 60～80 of per minutes is dripped system, splashes into in the refrigerative liquid paraffin of ice bath, after the shaping, ball is taken out, inhale the liquid Paraffin that goes to the ball surface with absorbent paper, make 1000, promptly.
More than form when producing and to increase or to reduce according to corresponding ratio, as large-scale production can be unit with kilogram or with the ton, small-scale production can be unit with the gram also, and weight can increase or reduce, but the crude drug material weight proportion constant rate between each composition.
In order to understand essence of the present invention better,, its new purposes in pharmaceutical field is described below by the result of the test of this pharmaceutical composition of clinical observation at anti-" aspirin resistance ".
The present invention adopts the research method to aspirin resistance commonly used at present, by measuring platelet aggregation rate, judge whether the patient has the effect that reduces aspirin resistance after taking medicine of the present invention, the present invention passes through clinical research observation, proved the application of medicine of the present invention in the medicine of the anti-aspirin resistance of preparation, medicine of the present invention has the effect of anti-aspirin resistance, in order to understand the present invention better, clinical test results with medicine of the present invention illustrates its new purposes in pharmaceutical field below, be convenient narration, below medicine of the present invention be called FUFANG DANSHEN DIWAN.
The experimental example FUFANG DANSHEN DIWAN reduces aspirin resistance effect experiment
We and year January in October, 2003 to 2004 carry out aspirin to 20 Yu Jia cadre's sanitarium retired cadres and family members under the Beijing Military Area Command and detect examination, filter out 86 of aspirin resistance patients (56 of men altogether, 29 of woman, 70.9 ± 10.9 years old age), find that the aspirin resistance incidence rate is about 15.6%.The aspirin resistance patient is divided into (55 of combination group; Unite and use aspirin and FUFANG DANSHEN DIWAN), single with Composite Salvia Dropping Pill group (31, the aspirin of stopping using, single FUFANG DANSHEN DIWAN of using), measure the platelet maximum agglutination rate once more after treating for 2 weeks.
Method:
One. inclusion criteria
1. take low-dosage aspirin continuously and surpass 2 all persons
2. use U.S. CHRON-LOG AGGREGOMETER 540VS and detect the platelet maximum agglutination rate of its arachidonic acid-induction greater than 30%
Meeting above-mentioned two persons simultaneously can be selected in
Two. exclusion standard:
1. disease in the blood system hemorrhage especially;
2. cancer
3. chronic obstructive pulmonary disease
The person promptly is excluded to meet the one
Three. grouping:
Combination group: select 55 aspirin resistance patients at random, continue to use aspirin, add simultaneously with 30/day of 2 all FUFANG DANSHEN DIWAN.
List is used Composite Salvia Dropping Pill group: select 31 aspirin resistance patients at random, the aspirin of stopping using is used 30/day of FUFANG DANSHEN DIWAN instead, 2 weeks.
Four. curative effect determinate standard
Produce effects: the platelet maximum agglutination rate is less than 30% (effect is equal to normal aspirin effect)
Effectively: the platelet maximum agglutination rate is greater than 30%, but is lower than for 80% (the platelet activation value normally suppresses effect but be lower than aspirin in normal range)
Invalid: the maximum agglutination rate excursion is ± 10% before and after the treatment
Raise: the maximum agglutination rate excursion is ± 10% before and after the treatment
Effective percentage=(produce effects number+effective number)/total number of persons
The result
One, aspirin resistance aspirin and FUFANG DANSHEN DIWAN are united use
1. treatment effective percentage
| Therapeutic effect | Number | Ratio % |
| The produce effects enabledisable raises | 46 1 1 7 | 83 2 2 13 |
The total effective rate that aspirin and FUFANG DANSHEN DIWAN are united use reaches 85% (47/55)
2. compare before and after the platelet maximum agglutination rate:
T-check: in pairs two sample average analyses
| Variable 1 | Variable 2 | |
| ((T≤t) the two tails of two tail T are critical for the critical P of the single tail of single tail t of T≤t) for average variance observation Poisson coefficient correlation hypothesis mean difference df t Stat P | 69.45454545 517.8821549 55 -0.06556464 0 54 8.534597132 6.82878E-12 1.673565748 1.36576E-11 2.004881026 | 27.76363636 714.776431 55 |
Before the treatment (69.5 ± 22.8), treatment 2 week backs (27.8 ± 26.7) are through paired t-test: p＜0.01; The average range of decrease tail 51.57% of platelet aggregation rate.
Annotate: value before reduction amplitude=(being worth after value-medication before the medication)/medication
Two. aspirin resistance stops aspirin, singly uses FUFANG DANSHEN DIWAN
1. treatment effective percentage
| Therapeutic effect | Number | Ratio % |
| The produce effects enabledisable raises | 12 3 5 11 | 39 10 16 35 |
Stop aspirin, single FUFANG DANSHEN DIWAN of using, the total effective rate that aspirin resistance is treated reaches 49% (15/31)
2. compare before and after the platelet maximum agglutination rate:
T-check: in pairs two sample average analyses
| Variable 1 | Variable 2 | |
| ((T≤t) the two tails of two tail T are critical for the critical P of the single tail of single tail t of T≤t) for average variance observation Poisson coefficient correlation hypothesis mean difference df t Stat P | 69.45454545 517.8821549 55 -0.06556464 0 54 8.534597132 6.82878E-12 1.673565748 1.36576E-11 2.004881026 | 27.76363636 714.776431 55 |
Before the treatment (80.4 ± 12.1), treatment 2 week backs (62.8 ± 38.2) are through paired t-test: p＜0.05; The average range of decrease tail 18.75% of platelet aggregation rate.
Annotate: value before reduction amplitude=(being worth after value-medication before the medication)/medication
Conclusion: to the aspirin resistance person, use aspirin and composite salvia dropping pill for curing can obviously lower platelet aggregation rate simultaneously, effective percentage is 85%, and the average range of decrease is 51.57%; Single its effective percentage is 49% with composite salvia dropping pill for curing aspirin resistance, and the average range of decrease is 18.75%.Presentation of results is to the invalid cardiovascular patient of independent use aspirin for treatment, FUFANG DANSHEN DIWAN and aspirin share has the effect of good curing aspirin resistance, use composite salvia dropping pill for curing aspirin resistance that effect is preferably also arranged separately, but the effect not as good as with the aspirin combination group, whether FUFANG DANSHEN DIWAN reduces aspirin resistance by other mechanism of action, the further research of still needing.
Medicine of the present invention is to be prepared from by following examples, and following specific embodiment is an explanation of the invention, can not limit the present invention.
The specific embodiment
Embodiment 1:
(a): get Radix Salviae Miltiorrhizae 45g, Radix Notoginseng 8g, Borneolum Syntheticum 0.5g, xylitol 12g, xanthan gum 3g is standby;
(b): get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water 5 times, collecting decoction filters, and filtrate concentrates, and adds 2 times of amount 90% ethanol, leaves standstill 20 hours, filter, and recovery ethanol, filtrate is concentrated under 50 ℃ of conditions, relative density is 1.15～1.25 thick paste (1);
(c): get Borneolum Syntheticum and be dissolved in the adequate amount of ethanol, get solution (2); (1) (2) are added in the xylitol and starch mixture of water-bath thawing, stir, insulation is 1.30～4.0 millimeters at 55～75 ℃ of temperature following system, dropper bore, drips system with the speed of 30～60 of per minutes, splash in the methyl-silicone oil, make 1000, after the shaping, ball is taken out, wipe away dried drop pill surface with absorbent paper, promptly.
Embodiment 2:
(a): get Radix Salviae Miltiorrhizae 150g, Radix Notoginseng 20g, Borneolum Syntheticum 1.5g, lactose 83g, starch 17g is standby;
(b): get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water 2 times, collecting decoction filters, and filtrate concentrates, and adds 4 times of amount 85～95% ethanol, leaves standstill 36 hours, filter, and recovery ethanol, filtrate is concentrated under 70～80 ℃ of conditions, relative density is 1.10～1.25 clear paste (1);
(c): get Borneolum Syntheticum and be dissolved in the adequate amount of ethanol, get solution (2); (1) (2) are added in the mixture of lactose that water-bath melts and starch, stir, insulation is 1.10～3.0 millimeters at 65～95 ℃ of temperature following system, dropper bore, drips system with the speed of 20～50 of per minutes, splash in the vegetable oil, make 1000 drop pill, after the shaping, ball is taken out, wipe away dried drop pill surface with absorbent paper, promptly.
Embodiment 3:
(a): get Radix Salviae Miltiorrhizae 100g, Radix Notoginseng 15g, Borneolum Syntheticum 0.8g, xylitol 37.5g, arabic gum 12.5g is standby;
(b): get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water 3 times, collecting decoction filters, and filtrate concentrates, and adds 4 times of amount 85～90% ethanol, leaves standstill 18 hours, filter, and recovery ethanol, filtrate is concentrated under 40～50 ℃ of conditions, relative density is 1.05～1.15 thick paste (1);
(c): get Borneolum Syntheticum and be dissolved in the adequate amount of ethanol, get solution (2); (1) (2) are added in the mixture of xylitol and arabic gum, fully mix, mixture is at 50～95 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, speed with 50～60 of per minutes is dripped system, splashes in the methyl-silicone oil, makes 1000 drop pill, after the shaping, ball is taken out, wipe away dried drop pill surface with absorbent paper, promptly.
Embodiment 4
(a): get Radix Salviae Miltiorrhizae 75g, Radix Notoginseng 14g, Borneolum Syntheticum 1.2g, xylitol 30.7, arabic gum 8.3g is standby;
(b): get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water 3 times, collecting decoction filters, and filtrate concentrates, and adds 3 times of amount 95% ethanol, leaves standstill 24 hours, filter, and recovery ethanol, filtrate is concentrated under 50～75 ℃ of conditions, relative density is 1.20～1.30 thick paste (1);
(c): get Borneolum Syntheticum and be dissolved in the adequate amount of ethanol, get solution (2); (1) (2) are added in the mixture of xylitol and arabic gum, fully mix, mixture is at 50～115 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, drips system with the speed of 20～60 of per minutes, splashes in 0～18 ℃ the liquid paraffin, back packing to be dried, make 1000 drop pill, after the shaping, ball is taken out, inhale the liquid Paraffin that goes to the ball surface with absorbent paper, promptly.
Embodiment 5
(a): get Radix Salviae Miltiorrhizae 115g, Radix Notoginseng 20g, Borneolum Syntheticum 1.0g, xylitol 36g, pregelatinized Starch 4g is standby;
(b): get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water 2～4 times, collecting decoction filters, filtrate concentrates, and adds 1～3 times of amount 90～97% ethanol, leaves standstill 18～30 hours, filter, reclaim ethanol, filtrate is concentrated under 50～75 ℃ of conditions, relative density is 1.20～1.40 thick paste (1);
(c): get Borneolum Syntheticum and be dissolved in the adequate amount of ethanol, get solution (2); (1) (2) are added in the xylitol and pregelatinized Starch mixture of water-bath thawing, fully mix, mixture stirs at 80～95 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.2～2.5 millimeters at 60～65 ℃ of temperature following system, dropper bore, drips system with the speed of 40～60 of per minutes, splash in 0～18 ℃ the methyl-silicone oil, make 1000 drop pill, back packing to be dried, promptly.
Embodiment 6
(a): get Radix Salviae Miltiorrhizae 40g, Radix Notoginseng 17.6g, Borneolum Syntheticum 1g, sorbitol 15.5, starch 4.5g is standby;
(b): get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water 3 times, collecting decoction filters, and filtrate concentrates, and adds 2 times of amount 95% ethanol, leaves standstill 24 hours, filter, and recovery ethanol, filtrate is concentrated under 60 ℃ of conditions, relative density is 1.20～1.40 thick paste (1);
(c): get Borneolum Syntheticum and be dissolved in the adequate amount of ethanol, get solution (2); (1) (2) are added in sorbitol and the starch mixture, stir evenly, mixture is at 50～75 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 60～65 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, speed with 60～80 of per minutes is dripped system, splashes in 0～18 ℃ the liquid paraffin, makes 1000 drop pill, after the shaping, ball is taken out, inhale the liquid Paraffin that goes to the ball surface with absorbent paper, promptly.
Embodiment 7
(a): get Radix Salviae Miltiorrhizae 90g, Radix Notoginseng 17.6g, Borneolum Syntheticum 1g, xylitol 14.6g, carrageenan 5.4g is standby;
(b): get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water three times, collecting decoction filters, and filtrate concentrates, and adds 2 times of amount 95% ethanol, leaves standstill 24 hours, filter, and recovery ethanol, filtrate is concentrated under 55～60 ℃ of conditions, relative density is 1.33～1.35 thick paste (1);
(c): get Borneolum Syntheticum and be dissolved in the adequate amount of ethanol, get solution (2); (1) (2) are added in xylitol and the carrageenan mixture, stir evenly, mixture is at 80～115 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, 70 ± 2 ℃ following system, drip system with the speed of 60～80 of per minutes, the dropper bore is 1.1～3.5 millimeters, splash in 0～18 ℃ the liquid vegetable oil, make 1000 drop pill, after the shaping, ball is taken out, inhale the liquid Paraffin that goes to the ball surface with absorbent paper, promptly.
Embodiment 8
(a): get Radix Salviae Miltiorrhizae 90g, Radix Notoginseng 17.6g, Borneolum Syntheticum 1g, lactose 16g, starch 4g is standby;
(b): get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water three times, collecting decoction filters, and filtrate concentrates, and adds 2 times of amount 95% ethanol, leaves standstill 24 hours, filter, and recovery ethanol, filtrate is concentrated under 55～60 ℃ of conditions, relative density is 1.33～1.35 thick paste (1);
(c): get Borneolum Syntheticum and be dissolved in the adequate amount of ethanol, get solution (2); (1) (2) are added in the mixture of lactose and starch, mixture stirs at 64 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.2～2.5 millimeters at 64 ℃ of temperature following system, dropper bore, drips system with the speed of 20～60 of per minutes, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, make 1000 drop pill, promptly
Embodiment 9
(a): get Radix Salviae Miltiorrhizae 90g, Radix Notoginseng 17.6g, Borneolum Syntheticum 1g, xylitol 14g, arabic gum 6g is standby;
(b): get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water three times, collecting decoction filters, and filtrate concentrates, and adds 2 times of amount 95% ethanol, leaves standstill 24 hours, filter, and recovery ethanol, filtrate is concentrated under 55～60 ℃ of conditions, relative density is 1.33～1.35 thick paste (1);
(c): get Borneolum Syntheticum and be dissolved in the adequate amount of ethanol, get solution (2); (1) (2) are added in the mixture of xylitol and arabic gum, mixture stirs at 64 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation, in following system of 64 ℃ of temperature, the dropper bore is 1.2～2.5 millimeters, speed with 20～40 of per minutes is dripped system, splash in 10 ℃ the methyl-silicone oil, to the greatest extent and wipe liquid coolant, back packing to be dried the drop pill drop that forms, make 1000 drop pill, promptly.
Embodiment 10
(a): get Radix Salviae Miltiorrhizae 41.06g, Radix Notoginseng 8.03g, Borneolum Syntheticum 0.46g, xylitol 12g, arabic gum 8g is standby;
(b): the Radix Salviae Miltiorrhizae of the coarse pulverization of learning from else's experience, pseudo-ginseng add 5 times of water gagings to extraction pot, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, decocts 1 hour, filters, and filtering residue discards, merging filtrate; Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 69～71%, leaves standstill 12 hours; Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol, the simmer down to relative density is 1.32～1.40 extractum;
(c): get above-mentioned extractum and Borneolum Syntheticum, evenly mixed with the mixture of xylitol and arabic gum, mixture stirs at 64 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.2～2.5 millimeters at 64 ℃ of temperature following system, dropper bore, splashes in 0 ℃ the methyl-silicone oil, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried is made drop pill, promptly.
Embodiment 11
(a): get Radix Salviae Miltiorrhizae 59.36g, Radix Notoginseng 6.38g, Borneolum Syntheticum 0.34g, lactose 11g, arabic gum 9g is standby;
(b): get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water three times, collecting decoction filters, and filtrate concentrates, and adds 2 times of amount 95% ethanol, leaves standstill 24 hours, filter, and recovery ethanol, filtrate is concentrated under 55～60 ℃ of conditions, relative density is 1.33～1.35 thick paste (1);
(c): get Borneolum Syntheticum and be dissolved in the adequate amount of ethanol, get solution (2); In the lactose that (1) (2) are added and the mixture of arabic gum, mixture stirs at 75 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation, in following system of 70 ℃ of temperature, the dropper bore is 1.2～2.5 millimeters, speed with 30～80 of per minutes is dripped system, splash in 0 ℃ the methyl-silicone oil, to the greatest extent and wipe liquid coolant, back packing to be dried the drop pill drop that forms, make 1000 drop pill, promptly.
Embodiment 12
(a): get Radix Salviae Miltiorrhizae 41.06g, Radix Notoginseng 8.03g, Borneolum Syntheticum 0.46g, lactose 15g, carboxymethyl starch 3g, arabic gum 2g are standby;
(b):. the Radix Salviae Miltiorrhizae of the coarse pulverization of learning from else's experience, pseudo-ginseng add 5 times of water gagings to extraction pot, decocted 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, decocts 1 hour, filters, and filtering residue discards, merging filtrate; Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 69～71%, leaves standstill 12 hours; Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol, the simmer down to relative density is 1.32～1.40 extractum.
(c): get above-mentioned extractum and Borneolum Syntheticum, with the ratio of weight be the mixture of lactose, carboxymethyl starch and the arabic gum of 1: 0.2～1:0.4, fully mix, mixture is at 80～95 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, and insulation is 1.21～2.5 millimeters at 60～85 ℃ of temperature following system, dropper bore, splash in 0～18 ℃ the vegetable oil, back packing to be dried is made drop pill, promptly.
Embodiment 13:
(a): get the extractum 7g for preparing by embodiment 8 methods, Borneolum Syntheticum 0.1g, xylitol 18.5g, starch 1.5g are standby;
(b): with xylitol and starch mix homogeneously, add above-mentioned extractum and Borneolum Syntheticum, mixture is at 75 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, and insulation is 1.2～2.5 millimeters at 60～70 ℃ of temperature following system, dropper bore, splash in 0 ℃ the methyl-silicone oil, speed with 50～60 of per minutes is dripped system, splashes in the methyl-silicone oil, makes 1000, after the shaping, ball is taken out, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, make 1000 drop pill, promptly.
Embodiment 14:
(a): it is standby to get the Radix Salviae Miltiorrhizae, Radix Notoginseng extractum 12.5g, Borneolum Syntheticum 3.2g, lactose 20g, the arabic gum 3.5g that obtain by embodiment 1 method;
(b) lactose is mixed with arabic gum, mixture adds above-mentioned extractum, Borneolum Syntheticum at 55～85 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, in following system of 60～75 ℃ of temperature, the dropper bore is 1.2～2.5 millimeters, drips system with the speed of 30～50 of per minutes, splashes in 5～10 ℃ the vegetable oil, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 15
(a): it is standby to get the Radix Salviae Miltiorrhizae, Radix Notoginseng extractum 5.5g, Borneolum Syntheticum 0.5g, xylitol 16.5g, the starch 3.5g that obtain by embodiment 7 methods;
(b) xylitol is mixed with starch, mixture adds above-mentioned extractum, Borneolum Syntheticum at 60～85 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, in following system of 60～85 ℃ of temperature, the dropper bore is 1.2～2.5 millimeters, drips system with the speed of 20～60 of per minutes, splashes in 5～15 ℃ the liquid paraffin, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 16
(a): it is standby to get the Radix Salviae Miltiorrhizae, Radix Notoginseng extractum 4.65g, Borneolum Syntheticum 0.85g, xylitol 15.5g, the arabic gum 4.5g that obtain by embodiment 4 methods;
(b) xylitol is mixed with arabic gum, mixture adds above-mentioned extractum, Borneolum Syntheticum at 65～85 ℃ of heating and meltings, stir, mixing time is 10～20 minutes, insulation, in following system of 60～65 ℃ of temperature, the dropper bore is 1.21～2.5 millimeters, drips system with the speed of 20～40 of per minutes, splashes in-10～15 ℃ the vegetable oil, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 17: the preparation method of FUFANG DANSHEN DIWAN
Get Radix Salviae Miltiorrhizae 90g, Radix Notoginseng 17.6g, Borneolum Syntheticum 1g, polyethylene glycol 6000 20g are standby;
Get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water three times, collecting decoction filters, filtrate concentrates, and adds 2 times of amount 95% ethanol, leaves standstill 24 hours, filters, recovery ethanol is concentrated into relative density 1.33～1.35 (55～60 ℃); Getting Borneolum Syntheticum is dissolved in the adequate amount of ethanol, (1) (2) are added in the Polyethylene Glycol of water-bath thawing, stir evenly, be incubated 70 ± 2 ℃, select the dropper of suitable bore for use, speed with 60～80 of per minutes is dripped system, splashes into in the refrigerative liquid paraffin of ice bath, after the shaping, ball is taken out, inhale the liquid Paraffin that goes to the ball surface with absorbent paper, make, 1000 promptly.
Embodiment 18: the preparation method of FUFANG DANSHEN DIWAN
Get Radix Salviae Miltiorrhizae 180g, Radix Notoginseng 25g, Borneolum Syntheticum 2g, polyethylene glycol 6000 30g are standby;
Get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water three times, collecting decoction filters, filtrate concentrates, and adds 2 times of amount 95% ethanol, leaves standstill 24 hours, filters, recovery ethanol is concentrated into relative density 1.33～1.35 (55～60 ℃); Getting Borneolum Syntheticum is dissolved in the adequate amount of ethanol, (1) (2) are added in the Polyethylene Glycol of water-bath thawing, stir evenly, be incubated 70 ± 2 ℃, select the dropper of suitable bore for use, speed with 60～80 of per minutes is dripped system, splashes into in the refrigerative liquid paraffin of ice bath, after the shaping, ball is taken out, inhale the liquid Paraffin that goes to the ball surface with absorbent paper, make, 1000 promptly.
Embodiment 19: the preparation method of FUFANG DANSHEN DIWAN
Get Radix Salviae Miltiorrhizae 115g, Radix Notoginseng 14g, Borneolum Syntheticum 1.2g, polyethylene glycol 6000 40g are standby;
Get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water three times, collecting decoction filters, filtrate concentrates, and adds 2 times of amount 95% ethanol, leaves standstill 24 hours, filters, recovery ethanol is concentrated into relative density 1.33～1.35 (55～60 ℃); Getting Borneolum Syntheticum is dissolved in the adequate amount of ethanol, (1) (2) are added in the Polyethylene Glycol of water-bath thawing, stir evenly, be incubated 70 ± 2 ℃, select the dropper of suitable bore for use, speed with 60～80 of per minutes is dripped system, splashes into in the refrigerative liquid paraffin of ice bath, after the shaping, ball is taken out, inhale the liquid Paraffin that goes to the ball surface with absorbent paper, make, 1000 promptly.
Embodiment 20: the preparation method of FUFANG DANSHEN DIWAN
Get Radix Salviae Miltiorrhizae 30g, Radix Notoginseng 40g, Borneolum Syntheticum 0.3g, polyethylene glycol 6000 40g are standby;
Get Radix Salviae Miltiorrhizae, Radix Notoginseng decocts with water three times, collecting decoction filters, filtrate concentrates, and adds 2 times of amount 95% ethanol, leaves standstill 24 hours, filters, recovery ethanol is concentrated into relative density 1.33～1.35 (55～60 ℃); Getting Borneolum Syntheticum is dissolved in the adequate amount of ethanol, (1) (2) are added in the Polyethylene Glycol of water-bath thawing, stir evenly, be incubated 70 ± 2 ℃, select the dropper of suitable bore for use, speed with 60～80 of per minutes is dripped system, splashes into in the refrigerative liquid paraffin of ice bath, after the shaping, ball is taken out, inhale the liquid Paraffin that goes to the ball surface with absorbent paper, make, 1000 promptly.
Claims (9)
1, the application of a kind of pharmaceutical composition in the low medicine that resists of the anti-aspirin of preparation, wherein the composition of said composition comprises 30～180 parts of Radix Salviae Miltiorrhizaes, 5～40 parts of Radix Notoginseng, 0.3～2.5 part of Borneolum Syntheticum, 10～40 parts of adjuvants.
2, application as claimed in claim 1 is characterized in that the composition of said composition comprises 75～115 parts of Radix Salviae Miltiorrhizaes, 14～20 parts of Radix Notoginseng, 0.8～1.2 part of Borneolum Syntheticum, 15～30 parts of adjuvants.
3, application as claimed in claim 2 is characterized in that the composition of said composition comprises 90 parts of Radix Salviae Miltiorrhizaes, 17.6 parts of Radix Notoginseng, 1 part of Borneolum Syntheticum, 20 parts of adjuvants.
4,, it is characterized in that the used adjuvant of said composition comprises Polyethylene Glycol as any one described application in the claim 1～3.
5, application as claimed in claim 4 is characterized in that the used adjuvant of said composition comprises polyethylene glycol 6000.
6,, it is characterized in that described compositions is a kind of of drop pill, spray, sublimed preparation, pill, granule, capsule, tablet, electuary, powder, oral liquid formulations form as any one described application in the claim 1～3.
7,, it is characterized in that the application of this pharmaceutical composition in the medicine of preparation treatment aspirin repellency cardiovascular and cerebrovascular disease as any one described application in the claim 1～3.
8, application as claimed in claim 7 is characterized in that said aspirin repellency cardiovascular and cerebrovascular disease is meant the invalid cardiovascular and cerebrovascular disease of use aspirin for treatment.
9, application as claimed in claim 8 is characterized in that said aspirin repellency cardiovascular and cerebrovascular disease is meant invalid coronary heart disease, the angina pectoris of use aspirin for treatment.
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100198381A CN100411641C (en) | 2004-06-30 | 2004-06-30 | Use of dripping pill in preparing medicine for treating anti-aspirin |
| AU2004290484A AU2004290484B8 (en) | 2003-08-28 | 2004-08-26 | Treatment of Aspirin Resistance with Radix Salviae Miltiorrhizae, its extract and composition |
| CA2537300A CA2537300C (en) | 2003-08-28 | 2004-08-26 | Treatment of asprin resistance with radix salviae miltiorrhizae, its extract and composition |
| JP2006524202A JP2007504099A (en) | 2003-08-28 | 2004-08-26 | Treatment of aspirin resistance using Tansan, its extract and composition |
| KR1020067004035A KR101210405B1 (en) | 2003-08-28 | 2004-08-26 | Radix salviae miltiorrhizaeextract and composition thereof for the treatment of the aspirin resistance diseases |
| US10/564,661 US20070071837A1 (en) | 2003-08-28 | 2004-08-26 | Treatment of aspirin resistance with radix salviae mitiorhizae, its extract and composition |
| PT47621255T PT1658879E (en) | 2003-08-28 | 2004-08-26 | Radix salviae miltiorrhizae, extract and composition thereof for the treatment of the aspirin resistance diseases |
| EP04762125A EP1658879B1 (en) | 2003-08-28 | 2004-08-26 | Radix salviae miltiorrhizae, extract and composition thereof for the treatment of the aspirin resistance diseases |
| EA200600471A EA010910B1 (en) | 2003-08-28 | 2004-08-26 | Treatment of the aspirin resistance using radix salviae miltiorrhizae, extract and composition thereof |
| PCT/CN2004/000989 WO2005049058A1 (en) | 2003-08-28 | 2004-08-26 | Radix salviae miltiorrhizae, extract and composition thereof for the treatment of the aspirin resistance diseases |
| DK04762125.5T DK1658879T3 (en) | 2003-08-28 | 2004-08-26 | Radix Salviae Miltiorrhizae, its extract and composition for the treatment of aspirin-resistant diseases |
| ES04762125T ES2405599T3 (en) | 2003-08-28 | 2004-08-26 | Radix Salviae Miltiorrhizae, extract and composition thereof for the treatment of aspirin resistant diseases |
| MYPI20043524A MY143282A (en) | 2003-08-28 | 2004-08-27 | Treatment of aspirin resistance with radix salviae miltiorrhizae, its extract and composition |
| NO20060832A NO335203B1 (en) | 2003-08-28 | 2006-02-21 | Treatment of aspirin resistance with radix sage miltiorrhiaze, its extract and composition. |
| HK06112754.5A HK1092090A1 (en) | 2003-08-28 | 2006-11-20 | Radix salviae miltiorrhizae, extract and composition thereof for the treatment of the aspirin resistance diseases |
| US12/194,879 US20080305189A1 (en) | 2003-08-28 | 2008-08-20 | Treatment of aspirin resistance with radix salviae miltiorrhizae, its extract and composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100198381A CN100411641C (en) | 2004-06-30 | 2004-06-30 | Use of dripping pill in preparing medicine for treating anti-aspirin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1714823A true CN1714823A (en) | 2006-01-04 |
| CN100411641C CN100411641C (en) | 2008-08-20 |
Family
ID=35821184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100198381A Expired - Lifetime CN100411641C (en) | 2003-08-28 | 2004-06-30 | Use of dripping pill in preparing medicine for treating anti-aspirin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100411641C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023173581A1 (en) * | 2022-03-18 | 2023-09-21 | 广州白云山奇星药业有限公司 | New use of huatuo zaizao pill |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1091306A (en) * | 1993-02-16 | 1994-08-31 | 郎恩千 | Brain-care pellet |
-
2004
- 2004-06-30 CN CNB2004100198381A patent/CN100411641C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023173581A1 (en) * | 2022-03-18 | 2023-09-21 | 广州白云山奇星药业有限公司 | New use of huatuo zaizao pill |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100411641C (en) | 2008-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1923227A (en) | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102028747B (en) | Drug for treating coronary heart disease and extraction method | |
| CN102028738B (en) | Medicament for treating coronary heart disease and preparation thereof | |
| JP2007504099A (en) | Treatment of aspirin resistance using Tansan, its extract and composition | |
| CN1714836A (en) | Use of medicine in preparing medicine for treating anti-aspirin | |
| CN1714823A (en) | Use of dripping pill in preparing medicine for treating anti-aspirin | |
| CN1872315A (en) | Application of medication of containing spatholobus stem in resistant medication anti aspirin | |
| CN1872317A (en) | Application of medication of containing red sage root in resistant medication anti aspirin | |
| CN1745768A (en) | Use of medicine containing Milkvetch Root against aspirin | |
| CN1714859A (en) | Use of composition containing red-rooted salvia root in preparing medicine for treating anti-aspirin | |
| CN1714837A (en) | Use of medicine containing haw in preparing medicine for treating anti-aspirin | |
| CN101884735B (en) | Medicament for treating dyslipidemia and preparation method thereof | |
| CN102028739B (en) | Drug for treating coronary heart disease and preparation method thereof | |
| CN1872312A (en) | Application of medication of containing red sage root in resistant medication anti aspirin | |
| CN1724026A (en) | Application of medicinal composition for preparing medicine for treating aspirin-resistance | |
| CN1872316A (en) | Medication of containing astragalus root in application for treating resistant medication of aspirin | |
| CN1724046A (en) | Application of medicine contg. sealwort for preparing medicine of anti-aspirin-resistance | |
| CN1872173A (en) | Application of composition of containing root-bark of peony in resistant medication anti aspirin | |
| CN1723974A (en) | Application of medicine contg. ligusticum wallichii for preparing medicine of anti-aspirn-resistance | |
| CN1714812A (en) | Use of medicine containing pseudo-ginseng and borneol in preparing medicine for treating anti aspirin | |
| CN1785271A (en) | Applicalsion of medicine containing salvia in anriaspirin medicine | |
| CN1872176A (en) | Application of medication of containing red sage root in treating resistant medication of aspirin | |
| CN1872313A (en) | Medication of containing curcuma root in application for treating resistant medication of aspirin | |
| CN1872249A (en) | Application of medication of containing red peony root in resistant medication anti aspirin | |
| CN1745767A (en) | Use of depot containing Chuanxiong against aspirin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |